Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novo Nordisk A/S ADR
(NY:
NVO
)
135.42
-5.45 (-3.87%)
Official Closing Price
Updated: 4:10 PM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novo Nordisk A/S ADR
< Previous
1
2
...
20
21
22
23
24
25
26
27
28
...
54
55
Next >
Ryan Cohen Plans to Save GameStop By Becoming Warren Buffett
December 14, 2023
Ryan Cohen's latest plan to save GME stock is transforming GameStop into Berkshire Hathaway. Will it work?
Via
InvestorPlace
Can Altimmune's weight-loss drug be a game-changer?
December 14, 2023
The runaway success of weight-loss drugs like Novo Nordisk A/S (NYSE: NVO) Ozempic and Eli Lilly and Co. (NYSE: LLY) Mounjaro has kicked off a gold
Via
MarketBeat
Exposures
Product Safety
3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024
December 13, 2023
These biotech stocks with promising pipelines are showing some major promise and growth potential for the new year.
Via
InvestorPlace
Obesity Drugs: Employers Embrace Virtual Healthcare to Manage Surging Costs
December 13, 2023
U.S.
Via
Benzinga
Weight Loss Drugs' Trickle Down Effect - Insurer Restrictions Create Access Challenges For Diabetes Patients
December 12, 2023
There is growing concern among some type 2 diabetes patients over challenges in obtaining reimbursement for medications like Novo Nordisk A/S's (NYSE: NVO) Ozempic amid stricter health plan
Via
Benzinga
Despite its growth, NYSE:NVO remains within the realm of affordability.
December 12, 2023
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) stands out as a growth opportunity that won't break the bank.
Via
Chartmill
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
December 08, 2023
Via
Benzinga
Better Growth Stock: Viking Therapeutics or Iovance Biotherapeutics?
December 12, 2023
Both of these pharma stocks could be big winners. But one stock screens as a better buy from a risk standpoint.
Via
The Motley Fool
Better Weight Loss Stock: Eli Lilly or Novo Nordisk?
December 12, 2023
Both of these pharma stocks have been top performers in 2023. One stock is the better long-term buy, however.
Via
The Motley Fool
What's Going On With Ozempic-Maker Novo Nordisk Stock?
December 11, 2023
Novo Nordisk A/S (NASDAQ: NVO) shares are moving Monday and the Ozempic-maker's stock has gained more than 40% year-to-date.
Via
Benzinga
Eli Lilly Skids, Weighing On Novo Nordisk, On A Key New Finding For Obesity Drugs
December 11, 2023
Researchers examined what happened after patients stopped taking Zepbound.
Via
Investor's Business Daily
Are These Biotechs Ready To Launch?
December 09, 2023
Biotech stocks are still in the process of repairing the damage from recent months — and recent years. Indeed, as of a month ago, the SPDR Biotech Fund had been dead money for an unbelievable eight and...
Via
Talk Markets
Bernie Sanders To Take On Ozempic, Wegovy, Weight Loss Drugs: 'Could Be Helpful, But They're Not Going To Be Helpful If People Can't Afford Them'
December 08, 2023
A hearing from the Senate led by Bernie Sanders will look at diabetes and the rise of weight loss drugs.
Via
Benzinga
Everyone Is Talking About This Stock. Is It a Good Long-Term Option?
December 02, 2023
This company famously helps manage a prevalent chronic illness.
Via
The Motley Fool
Why Viking Therapeutics Was Crushing It This Week
December 08, 2023
Nowadays, it's good to be a developer of next-generation weight loss drugs.
Via
The Motley Fool
Could Eli Lilly Beat Novo Nordisk in the Billion-Dollar Weight Loss Market?
December 08, 2023
These drugs address a rapidly growing market.
Via
The Motley Fool
Zoetis Stock A Good Companion For Your Portfolio? Shares Rising
December 07, 2023
Reflecting strong fundamentals, Zoetis stock boasts a best-possible A SMR Rating (sales+profit margins+return on equity) on an A-to-E scale.
Via
Investor's Business Daily
JNJ CEO Signals No Rush Into Weight-Loss Drug Realm, Emphasizes Different Priorities
December 06, 2023
Johnson & Johnson (NYSE: JNJ) has no immediate plans to venture into weight-loss drugs due to the existing competition saturation, as Chief Executive Officer
Via
Benzinga
Obesity Drugs: Greater Weight Loss Linked to Prolonged Use of Novo Nordisk's Wegovy
December 06, 2023
A recent analysis of medical records and insurance claims data revealed that 40% of patients who received prescriptions for Novo Nordisk A/S's (NYSE: NVO) obesity treatment drug Wegovy in 2021 or 2022...
Via
Benzinga
Simply Good Foods: Winner in the Ozempic Weight-Loss Trend
December 06, 2023
Nutritional food and snacks producer The Simply Good Foods Co. (NASDAQ: SMPL) has seen its shares rocket higher on the weight-loss medication
Via
MarketBeat
Jim Cramer Highlights 'Transformational' Impact Of Weight Loss Drugs Like Ozempic: Focus Now On 'Potential Winners' From The Same Narrative
December 04, 2023
Via
Benzinga
Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market
December 04, 2023
Weight-loss drugs such as Ozempic and Mounjaro are the leading blockbusters for a new epidemic
Via
Benzinga
Roche Stock Rises On $3.1 Billion Deal For Obesity Drugmaker
December 04, 2023
Roche said it will spend up to $3.1 billion to acquire Carmot Therapeutics, a biotech firm developing obesity drugs. Roche stock gained on the news.
Via
Investor's Business Daily
Ozempic vs. Mounjaro:: Battle of the bulge
December 04, 2023
The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs, led by the popularity of Ozempic. Celebrity usage
Via
MarketBeat
Exposures
Product Safety
Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs
December 04, 2023
Roche Holding AG (OTC: RHHBY) has agreed to
Via
Benzinga
1 Stock-Split Stock to Buy Hand Over Fist in December, and 1 to Avoid Like the Plague
December 04, 2023
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there's a historically cheap outperformer, as well as an industry leader that could...
Via
The Motley Fool
3 No-Brainer Growth Stocks to Buy in December
December 03, 2023
No analysis paralysis is required with these great stocks.
Via
The Motley Fool
Pfizer Tumbles After Abandoning Weight-Loss Pill
December 02, 2023
With shares already reflecting a post-COVID dearth of revenue streams, Pfizer's growth outlook recently took another hit as it halted development of its experimental weight-loss pill after a high rate...
Via
Talk Markets
An Important History Lesson for Gene-Editing Investors
December 02, 2023
Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy.
Via
The Motley Fool
Is Eli Lilly a Better Stock to Buy and Hold Over the Next 10 Years Than Novo Nordisk?
December 02, 2023
Both of these stocks have been big winners this year. But one could be better positioned to extend that winning streak over the next decade.
Via
The Motley Fool
< Previous
1
2
...
20
21
22
23
24
25
26
27
28
...
54
55
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.